Coronary Revascularization
To the Editor:
Dr. Sabiston's discussion of coronary revascularization (Circulation, 43: 175, 1971 ) ably presents the state of the art. It was, therefore, disappointing to search this paean to twentieth century surgical technology for an equally contemporary approach to evaluation of its therapeutic results: there is no mention of controlled clinical trials. Instead, we learn that we shall have to depend on the traditional approach -the "natural history" of recurrent myocardial infarction. This is the common basis of claims for many discarded medical and surgical treatments -the tried and untrue method. Such treatments had performed spectacularly in publications by their originators and proponents.
The verdict of properly controlled trials of many pharmacologic therapies has usually been no improvement over placebo. By contrast, surgical methods have not been examined rigorously, excepting internal mammary ligation. Its advocates reported remarkable results, but carefully designed series yielded equal subjective and objective changes in control patients. More recently we have witnessed the same phenomenon-improvement in patients with occluded Vineberg implants.
In fairness, one cannot argue that coronary bypass can be viewed as skeptically as earlier methods. Rapid improvements in ventricular function are truly impressive, while longevity and the actual placebo-effect on angina remain uncertain. But need we continue the traditional, time-dishonored approach of trial-and-error, i.e., operations on large numbers of patients, followed by reviews to sort out what happened, identification of the mistakes, and then decisions on how they should have been applied for future use? Moreover, without prospective substratification (individual targeting for anginal dysfunction/ longevity) and adequate standards of comparison (matched, randomly allotted control patients) the effort balances shakily on recollections of "natural history" which still suffers from "a lack of precise definition."
The F.D.A., therapeutic trials committees, granting authorities, and responsible journal reviewers require airtight controlled trials of new (and, thank heaven, old) pills and injections. Somehow, the mystique of surgery-the presumed efficacy of a mechanical rearrangement of tissue-makes these natural referees suspend disbelief in a way that no pill could. 81: 149, 1971 ) amply reviews the difficulties encountered in establishing and completing such studies.
In the development of a controlled clinical trial, those responsible should be convinced first that the study can be performed in a practical and workable manner that will produce results that are completely objective. In randomizing candidates for direct venous graft revascularization, many knowledgeable physicians doubt seriously that such a controlled study can be accomplished effectively. Dr. Eugene A. Stead, Jr., among others, has emphasized that once a group or center is recognized as randomizing such patients referral patterns become altered in a manner unfavorable for a proper study. Moreover, Circulation, Volume XLIV, August 1971
